Ascentage Pharma
800 King Farm Blvd.
Suite 300
Rockville
MD
20850
United States
Website: http://www.ascentagepharma.com/
162 articles about Ascentage Pharma
-
Ascentage Pharma Announces First Patient Dosed in the Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for the Treatment of Patients with Chronic Hepatitis B
6/17/2020
Ascentage Pharma announced that the Phase II clinical study of the company's novel inhibitor of apoptosis proteins antagonist APG-1387 in combination with entecavir for the treatment of patients with CHB has dosed its first patient in China.
-
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
5/31/2020
Ascentage Pharma announced that the company presented four posters of the latest clinical data on three of its drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor palcitoclax or APG-1252, and IAP inhibitor APG-1387, at the 2020 American Society of Clinical Oncology Annual Meeting.
-
Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting
5/15/2020
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the latest research progress of the company will be presented at the 2020 American Association for Cancer Research Annual Meeting.
-
Ascentage Pharma to Release Clinical Advances at 2020 ASCO Annual Meeting
5/11/2020
Ascentage Pharma announced that latest clinical data of the company's drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor APG-1252, and IAP inhibitor APG-1387, will be presented in three poster discussions and a poster at the 2020 American Society of Clinical Oncology Annual Meeting.
-
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation by the US FDA, Marking Another Milestone in Its Development
5/7/2020
Ascentage Pharma announced that the US Food and Drug Administration has granted HQP1351, the Company's core drug candidate, a Fast Track Designation for the treatment of patients with chronic myeloid leukemia with certain genetic mutations who have failed to respond to treatments with existing tyrosine kinase inhibitors.
-
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia
5/4/2020
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted HQP1351, the Company's core drug candidate, an Orphan Drug Designation for the treatment of chronic myeloid leukemia.
-
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China
4/7/2020
Ascentage Pharma announced that it has received approval from the Center for Drug Evaluation of the China National Medical Products Administration for the Phase Ib/II study of APG-2575, the company's novel Bcl-2‒selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development
3/30/2020
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, released its annual results for the year ended December 31, 2019.
-
Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States
3/23/2020
Ascentage Pharma announced that the global Phase Ib/II clinical study of APG-2575, a Bcl-2 selective inhibitor, as a single agent or in combination for the treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, has dosed its first patient in the United States.
-
Ascentage Pharma Announces Clearances for Three Phase Ib/II Clinical Studies of APG-2575 in China and the U.S., Beginning Simultaneous Clinical Development in Three Hematologic Malignancy Indications
3/9/2020
Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that two clinical studies of APG-2575, a novel Bcl-2 selective inhibitor being developed by Ascentage Pharma, have recently received clearances from the U.S. Food and Drug Administration (FDA)
-
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China
2/24/2020
SUZHOU, China and ROCKVILLE, MD ., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has received approval from Center of Drug Evaluation (CDE), China NMPA, for the Phase Ib/I
-
Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
12/10/2019
At the 61st American Society of Hematology Annual Meeting
-
Ascentage Pharma Breaks Ground on its Global Headquarters, R&D Center and Manufacturing Facility in the Suzhou Industrial Park
11/21/2019
Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies, announced that the groundbreaking ceremony for the Company's global headquarters, R&D center, and manufacturing facility took place at the Suzhou Industrial Park/
-
Ascentage Pharma and Henlius Form a Combination Therapy Strategic Collaboration
11/4/2019
Ascentage Pharma announced a combination therapy strategic collaboration with Henlius, working together to conduct clinical trials of the combination therapy between APG-2575, a novel, orally administered Bcl-2 selective inhibitor developed by Ascentage Pharma, and HLX01, the first launched product by Henlius, for the treatment of chronic lymphocytic leukemia in the People's Republic of China.
-
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
7/22/2019
Ascentage Pharma, announced that the company was notified by the U.S. Food & Drug Administration on the clearance of the Investigational New Drug application which allows the company to initiate its Phase Ib clinical trial of HQP1351, a novel drug candidate developed by Ascentage Pharma, for the treatment of patients with tyrosine kinase inhibitors-resistant chronic myeloid leukemia in the United States.
-
Ascentage Pharma announces first patient dosed in Phase I clinical trial of APG-2575 in China as the first China-made Bcl-2 Inhibitor
7/15/2019
Ascentage Pharma announced that the company recently dosed the first patient successfully in a Phase I clinical trial of APG-2575, a novel Bcl-2 selective inhibitor, for the treatment of hematologic malignancies in China.
-
Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO
6/4/2019
Ascentage Pharma announced that the company presented new data of two apoptosis-targeted drug candidates APG-115 and APG-1387 at the 55th Annual Meeting of the American Society of Clinical Oncology.
-
Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers
5/23/2019
Ascentage Pharma announced the presentation of new clinical data for its investigational apoptosis-targeted drug candidates at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.
-
Ascentage Pharma Announces Clinical Collaboration with Junshi Bioscience to Evaluate the Combination of APG-1387 and Toripalimab in Treating Cancers
4/8/2019
Ascentage Pharma announced that it has entered into a strategic collaboration with Shanghai Junshi Biosciences Co., Ltd. to explore the synergies of Ascentage's Inhibitor of Apoptosis Proteins (IAP) inhibitor APG-1387, and Junshi Biosciences' anti-PD-1 therapy toripalimab in clinical trials in solid and hematological tumors in China.
-
Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting
3/25/2019
Ascentage Pharma announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research annual meeting in Atlanta, March 29-April 3, 2019.